T
Tom B. Davidson
Researcher at Children's Hospital Los Angeles
Publications - 35
Citations - 1179
Tom B. Davidson is an academic researcher from Children's Hospital Los Angeles. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 21 publications receiving 696 citations. Previous affiliations of Tom B. Davidson include University of Southern California & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Timothy F. Cloughesy,Aaron Mochizuki,Joey Orpilla,Willy Hugo,Alexander Lee,Tom B. Davidson,Anthony C. Wang,Benjamin M. Ellingson,Julie A. Rytlewski,Catherine Sanders,Eric S. Kawaguchi,Lin Du,Gang Li,William H. Yong,Sarah C. Gaffey,Adam L. Cohen,Ingo K. Mellinghoff,Eudocia Q. Lee,David A. Reardon,Barbara O’Brien,Nicholas Butowski,Phioanh L. Nghiemphu,Jennifer Clarke,Isabel Arrillaga-Romany,Howard Colman,Thomas Kaley,John de Groot,Linda M. Liau,Patrick Y. Wen,Robert M. Prins +29 more
TL;DR: It is suggested that the neoadjuvant administration of PD-1 blockade enhances both the local and systemic antitumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor.
Journal ArticleDOI
TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination
Melody Hsu,Shaina Sedighim,Tina Wang,Joseph Antonios,Richard Everson,Alexander M. Tucker,Lin Du,Ryan O. Emerson,Erik Yusko,Catherine Sanders,Harlan Robins,William H. Yong,Tom B. Davidson,Gang Li,Linda M. Liau,Robert M. Prins +15 more
TL;DR: Higher degrees of overlap, or the development of an increased overlap following immunotherapy, was correlated with improved clinical outcome, and may provide insights into the successful, antigen-specific immune response.
Journal ArticleDOI
Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation
Tom B. Davidson,Alexander Lee,Melody Hsu,Shaina Sedighim,Joey Orpilla,Janet Treger,Maximilian Mastall,Saskia Roesch,Carmen Rapp,Mildred Galvez,Aaron Mochizuki,Joseph Antonios,Alejandro J. Garcia,Nikesh Kotecha,Nicholas L. Bayless,David Nathanson,Anthony C. Wang,Richard Everson,William H. Yong,Timothy F. Cloughesy,Linda M. Liau,Christel Herold-Mende,Robert M. Prins +22 more
TL;DR: The evidence suggests that PD-1 expression in patients with glioma reflects chronically activated effector T cells that display hallmarks of memory and exhaustion depending on its anatomic location.
Journal ArticleDOI
Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child with Pierre-Robin sequence (including cleft palate) and neurofibromatosis 2 (NF2): a case report and review of the literature
Tom B. Davidson,Tom B. Davidson,Pedro A. Sanchez-Lara,Pedro A. Sanchez-Lara,Linda M. Randolph,Linda M. Randolph,Mark D. Krieger,Mark D. Krieger,Shi-Qi Wu,Shi-Qi Wu,Ashok Panigrahy,Ashok Panigrahy,Hiroyuki Shimada,Hiroyuki Shimada,Anat Erdreich-Epstein,Anat Erdreich-Epstein +15 more
TL;DR: This report describes a NF2-adjacent chromosome 22q12.2 deletion syndrome and is the first to report association of MN1 deletion with abnormal craniofacial development and/or cleft palate in humans.
Journal ArticleDOI
A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors
Rajkumar Venkatramani,Marcio H. Malogolowkin,Tom B. Davidson,William A. May,William A. May,Richard Sposto,Leo Mascarenhas +6 more
TL;DR: Iinotecan 50 mg/m2/day for 5 days was the MTD when combined with vincristine, temozolomide and bevacizumab administered on a 21 day schedule and encouraging anti-tumor activity was noted.